StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Friday. The firm issued a hold rating on the medical equipment provider’s stock.

IRIDEX Price Performance

NASDAQ IRIX opened at $1.51 on Friday. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65. The firm has a market capitalization of $25.04 million, a PE ratio of -2.25 and a beta of 0.84. The company’s 50 day simple moving average is $1.65 and its 200 day simple moving average is $1.73. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.